{"id":"W4402561837","doi":"10.1016/j.annonc.2024.08.158","title":"150P Phase I/IIa trial of CD200R1 inhibitor 23ME-00610: Exploratory analyses of tissue-based and genetic biomarkers","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"S100 Proteins and Annexins","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Chugai Pharmaceutical; EMD Serono; Genentech; Sierra Oncology; Dutch Colorectal Cancer Group; PharmaMar; Government of the United Kingdom; European Society for Medical Oncology; Sociedad Española de Oncología Médica; Shionogi; Astellas Pharma; Eisai; National Institute for Health and Care Research; Seagen; Pfizer; NuCana; Incyte; BeiGene; Medical Research Council; Les Laboratories Pierre Fabre; AstraZeneca; Novocure; Regeneron Pharmaceuticals; Sarcoma UK; Sanofi; Exelixis; Eli Lilly and Company; American Society of Clinical Oncology; Daiichi Sankyo Europe; CRIS Cancer Foundation; Servier; Gilead Sciences; Amgen; Celgene","keywords":"Medicine; Exploratory analysis; Computational biology; Oncology; Pharmacology; Internal medicine; Data science","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009755061,0.001004128,0.001336897,0.0002866903,0.000258949,0.001411024,0.0004820822,0.0008858652,0.003083965],"category_scores_gemma":[0.0005634624,0.0002982566,0.000855209,0.0003281294,0.0005214663,0.000665008,0.0002882718,0.002576056,0.0009374365],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001101079,"about_ca_system_score_gemma":0.0009684257,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007352144,"about_ca_topic_score_gemma":0.002879132,"domain_scores_codex":[0.9997316,0.00009118731,0.000007205985,0.00005805501,0.00003794928,0.0000740648],"domain_scores_gemma":[0.9997212,0.00005264333,0.00004207777,0.00003614388,0.00001784736,0.0001299904],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4424058,0.01605718,0.03376191,0.0007134947,0.003726318,0.001075789,0.000260754,0.008020747,0.1319232,0.002321559,0.01980113,0.3399322],"study_design_scores_gemma":[0.3489234,0.3910896,0.1543357,0.0002496629,0.003882992,0.003225712,0.0003758335,0.01201257,0.03348949,0.007101607,0.04511906,0.0001944265],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9823323,0.003787235,0.001190427,0.001597778,0.000150535,0.0008073776,0.003477051,0.0001721191,0.006485207],"genre_scores_gemma":[0.9801148,0.001789023,0.002140911,0.002044431,0.0001018282,0.0007589613,0.006277509,0.00005930703,0.006713251],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003083965,"threshold_uncertainty_score":0.01031691,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1034689317333473,"score_gpt":0.4347685458059405,"score_spread":0.3312996140725932,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}